The National Institute for Health and Care Excellence (Nice) recommends Mounjaro (tirzepatide) for individuals with a BMI over 35 and weight-related illnesses. The rollout will be phased over 12 years to manage demand and protect other NHS services.
The NHS spending watchdog has recommended Mounjaro for those with a BMI of more than 35 and at least one weight-related illness. The NHS spending watchdog has recommended Mounjaro for those with a BMI of more than 35 and at least one weight-related illness.who are eligible for what has been dubbed the “King Kong of weight loss drugs” will initially be able to access it on the NHS after officials said they would prioritise people with the highest needs.
The “difficult decision” to roll out Mounjaro slowly over 12 years was made “in order to protect other vital NHS services”, the National Institute for spending watchdog has recommended the jab – also known as tirzepatide and made by Eli Lilly – for those with a body mass index (BMI) of more than 35 and at least one weight-related illness. This is estimated to account for about 3.4 million people. To help the NHS manage demand, Nice said about 220,000 people could benefit from the drug in an initial three-year period. After this, the situation will be reviewed by Nice, which will provide further guidance on the rollout. Mounjaro is a glucagon-like peptide-1 (GLP-1) agonist, a family of medications that help manage blood sugar. It was given the green light initially to help manage obesity on the NHS in June as part of draft guidance from Nice. The once-weekly jab should be prescribed alongside a reduced-calorie diet and exercise to help people lose weight.Prof Jonathan Benger, the chief medical officer at Nice, said: “The world will look very different in three years which is why we’ve taken the unprecedented decision to review the way this medicine is delivered to patients then. “Tirzepatide and other drugs like it, such as semaglutide, will help people living with obesity to lose weight, and as a result will reduce their risk of developing heart disease or having a stroke. “But tirzepatide is not for everybody, and only those with the highest clinical need will be treated initiall
Mounjaro Weight Loss NHS Obesity Tirzepatide
Australia Latest News, Australia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
How does weight loss drug Mounjaro work and why is it in such high demand?The ‘King Kong of weight loss drugs’ will be available on the NHS but only patients with most need will get it
Read more »
Putin approves record defence spending - a third of Russia's budgetPresident Vladimir Putin has approved setting aside a staggering third of government spending for the nation&x27;s armed forces.
Read more »
Weak Economic Growth Amid High Government Spending and ImmigrationEconomic figures show a soft economy with its seventh consecutive quarterly recession, highlighting the role of government spending and immigration in sustaining growth. The Reserve Bank's decision on interest rates remains uncertain.
Read more »
Australia's economy growing at slowest pace in decades, propped up by government spendingAustralia's economy is growing at its slowest pace in decades, with government support keeping households afloat.
Read more »
Starmer to pledge cuts to NHS waiting lists and crime in major reset for LabourAmbitious targets to improve voters’ lives come amid plunging approval ratings for government and loss of transport secretary
Read more »
NHS Doctor's £2.3m Crypto Portfolio Inspires Friends to InvestA London-based NHS doctor, Miles, shares his journey into crypto investing, which has seen his portfolio grow to £2.3m. His success has prompted friends to invest, with many viewing the recent surge in crypto prices as a golden opportunity.
Read more »